Imaging drug that illuminates ovarian cancer tissue when exposed to fluorescent light gets FDA approval

By | December 1, 2021
The U.S. Food and Drug Administration (FDA) today approved an imaging drug known as Cytalux (pafolacianine), which is attracted to ovarian cancer tissue and illuminates it when exposed to fluorescent light, allowing surgeons to more easily find and more precisely remove the cancer.